The stock of Soleno Therapeutics Inc (NASDAQ:SLNO) last traded at $20.67, down -22.87% from the previous session.
Data from the available sources indicates that Soleno Therapeutics Inc (NASDAQ:SLNO) is covered by 3 analysts. The consensus rating among analysts is ‘Buy’. SLNO stock price is now 304.67% away from the 50-day moving average and 465.25% away from the 200-day moving average. The market capitalization of the company currently stands at $206.49M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
In total, 0 analysts have assigned it a hold rating, and 3 have given it a buy rating.
With the price target of $8, Guggenheim recently initiated with Buy rating for Soleno Therapeutics Inc (NASDAQ: SLNO).
In other news, PERCEPTIVE ADVISORS LLC, 10% Owner bought 200 shares of the company’s stock on Jun 06. The stock was bought for $1,186 at an average price of $5.93. Upon completion of the transaction, the 10% Owner now directly owns 2,207,753 shares in the company, valued at $45.63 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 05, 10% Owner PERCEPTIVE ADVISORS LLC bought 78,468 shares of the business’s stock. A total of $469,239 was incurred on buying the stock at an average price of $5.98. This leaves the insider owning 2,207,553 shares of the company worth $45.63 million. Insiders disposed of 430,071 shares of company stock worth roughly $8.89 million over the past 1 year. A total of 18.99% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SLNO stock. A new stake in Soleno Therapeutics Inc shares was purchased by PERCEPTIVE ADVISORS LLC during the first quarter worth $45,634,000. VISIONPOINT ADVISORY GROUP, LLC invested $3,000 in shares of SLNO during the first quarter. In total, there are 24 active investors with 38.99% ownership of the company’s stock.
With an opening price of $23.43 on Wednesday morning, Soleno Therapeutics Inc (NASDAQ: SLNO) set off the trading day. During the past 12 months, Soleno Therapeutics Inc has had a low of $0.85 and a high of $30.30. As of last week, the company has a debt-to-equity ratio of 0.04, a current ratio of 2.33, and a quick ratio of 2.33. The fifty day moving average price for SLNO is $5.41 and a two-hundred day moving average price translates $3.76 for the stock.
The latest earnings results from Soleno Therapeutics Inc (NASDAQ: SLNO) was released for Jun, 2023.
